Collaboration OpportunitiesCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.

Merger And DevelopmentThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.

Technological AdvancementThe new user-filled Optejet incorporates a sterile disposable cartridge that can be user-filled from a traditional eyedropper bottle, allowing consistent and precise spray delivery.

Bears Say

Clinical Trial ChallengesThe Phase 3 CHAPERONE trial failure for MicroPine has informed the assumptions for the price target.

Discontinued TrialsThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.

Market And Revenue RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.

HYPD FAQ

What was Hyperion DeFi’s price range in the past 12 months?

Hyperion DeFi lowest stock price was $0.85 and its highest was $93.70 in the past 12 months.

What is Hyperion DeFi’s market cap?

Hyperion DeFi’s market cap is $39.67M.

When is Hyperion DeFi’s upcoming earnings report date?

Hyperion DeFi’s upcoming earnings report date is Aug 06, 2025 which is tomorrow.

How were Hyperion DeFi’s earnings last quarter?

Hyperion DeFi released its earnings results on May 19, 2025. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.59.

Is Hyperion DeFi overvalued?

According to Wall Street analysts Hyperion DeFi’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hyperion DeFi pay dividends?

Hyperion DeFi does not currently pay dividends.

What is Hyperion DeFi’s EPS estimate?

Hyperion DeFi’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hyperion DeFi have?

Hyperion DeFi has 5,603,034 shares outstanding.

What happened to Hyperion DeFi’s price movement after its last earnings report?

Hyperion DeFi reported an EPS of -$1.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 47.788%.

Which hedge fund is a major shareholder of Hyperion DeFi?

Currently, no hedge funds are holding shares in HYPD

Hyperion DeFi Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-77.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Hyperion DeFi

A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.